RE: Doubling3 Jan 2025 11:19
“ Encouraging interim results from the SCOPE trial have shown Scancell's SCIB1 vaccine, in combination with checkpoint inhibitors, significantly outperforming current standards of care.
With 80 per cent progression-free survival at 25 weeks, the trial underscores the potential of SCIB1 and its successor, iSCIB1+, which expands the treatable population and could address a $9 billion market opportunity.
Beyond its vaccine candidates, Scancell's GlyMab antibody platform has caught the attention of pharmaceutical giants.”